Open AccessCirculating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer
Author(s) -
Susan G. R. McDuff,
Karin M. Hardiman,
Peter Ulintz,
Aparna R. Parikh,
Hui Zheng,
Daniel W. Kim,
Jochen K. Lennerz,
Mehlika Hazar-Rethinam,
Emily E. Van Seventer,
Isobel J. Fetter,
Brandon Nadres,
Christine E. Eyler,
David P. Ryan,
Colin D. Weekes,
Jeffrey W. Clark,
James C. Cusack,
Lipika Goyal,
Andrew X. Zhu,
Jennifer Y. Wo,
Lawrence S. Blaszkowsky,
Jill N. Allen,
Ryan B. Corcoran,
Theodore S. Hong
Publication year - 2021
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.20.00220
Subject(s) - colorectal cancer , medicine , oncology , neoadjuvant therapy , chemoradiotherapy , cancer , breast cancer
This study was designed to assess the ability of perioperative circulating tumor DNA (ctDNA) to predict surgical outcome and recurrence following neoadjuvant chemoradiation for locally advanced rectal cancer (LARC).